A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia
Dinaciclib is a cyclin-dependent kinase (CDK) inhibitor, specific for CDK 1, 2, 5 and 9.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Participant Progression Free Survival
From date of randomization up to approximately 38 months
No
United States: Food and Drug Administration
P07714
NCT01580228
August 2012
April 2016
Name | Location |
---|---|
Call for Information (Investigational Site 0035) | Canton, Ohio 44718 |
Call for Information (Investigational Site 0006) | Fort Collins, Colorado 80615 |
Call for Information (Investigational Site 0268) | Chicago, Illinois 60637 |
Call for Information (Investigational Site 0003) | Billings, Montana 59101 |
Call for Information (Investigational Site 0007) | Hackensack, New Jersey 07601 |
Call for Information (Investigational Site 0265) | Bronx, New York 10461 |
Call for Information (Investigational Site 0101) | Portland, Oregon 97225 |
Call for Information (Investigational Site 0144) | Portland, Oregon 97213 |
Call for Information (Investigational Site 0048) | Sayre, Pennsylvania 18840 |
Call for Information (Investigational Site 0118) | Dallas, Texas 75390 |
Call for Information (Investigational Site 0269) | Temple, Texas 76508 |